Aurinia Pharmaceuticals Inc Company Profile
NASDAQ: AUPHHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Aurinia Pharmaceuticals at a glance
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Edmonton, AB, Canada. Aurinia Pharmaceuticals is led by Mr. Kevin C. Tang and employs about 128 people. At a market capitalization of $2.13 billion, it is considered a mid-cap company.
Its SEC Central Index Key (CIK) is 0001600620, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Aurinia Pharmaceuticals do?
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
Business description based on the company's public filings.
Company information
- Legal name
- Aurinia Pharmaceuticals Inc
- Ticker
- NASDAQ: AUPH
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Kevin C. Tang
- Employees
- 128
- Headquarters
- #140, 14315 – 118 Avenue, Edmonton, AB, Canada
- Phone
- 250 744 2487
- Website
- auriniapharma.com
- Market cap
- $2.13B
- SEC CIK
- 0001600620
- Latest annual report
- 10-K · Feb 26, 2026
Companies similar to Aurinia Pharmaceuticals
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| VERAVera Therapeutics Inc. Class A | 29.73 | -1.72% | $2.14B | vs AUPH |
| PHVSPharvaris N.V. | 31.12 | -1.77% | $2.18B | vs AUPH |
| PRGOPerrigo Company plc | 14.50 | -0.34% | $2.01B | vs AUPH |
| BHCBausch Health Companies Inc. | 6.04 | -1.79% | $2.26B | vs AUPH |
| PBHPrestige Consumer Healthcare Inc. | 47.87 | +0.63% | $2.27B | vs AUPH |
| SLSSELLAS Life Sciences Group Inc. | 11.26 | -0.44% | $2.27B | vs AUPH |
| MLYSMineralys Therapeutics Inc. | 22.38 | +1.31% | $1.98B | vs AUPH |
| SDGRSchrodinger Inc. | 26.39 | -3.30% | $1.97B | vs AUPH |